Tomoyasu Wakuda, Seico Benner, Yukari Uemura, Tomoko Nishimura, Masaki Kojima, Miho Kuroda, Kaori Matsumoto, Chieko Kanai, Naoko Inada, Taeko Harada, Yosuke Kameno, Toshio Munesue, Jun Inoue, Kazuo Umemura, Aya Yamauchi, Nanayo Ogawa, Itaru Kushima, Satoshi Suyama, Takuya Saito, Junko Hamada, Yukiko Kano, Nami Honda, Saya Kikuchi, Moe Seto, Hiroaki Tomita, Noriko Miyoshi, Megumi Matsumoto, Yuko Kawaguchi, Koji Kanai, Manabu Ikeda, Itta Nakamura, Shuichi Isomura, Yoji Hirano, Toshiaki Onitsuka, Norio Ozaki, Hirotaka Kosaka, Takashi Okada, Hitoshi Kuwabara, Hidenori Yamasue
Although oxytocin may provide a novel therapeutics for the core features of autism spectrum disorder (ASD), previous results regarding the efficacy of repeated or higher dose oxytocin are controversial, and the underlying mechanisms remain unclear. The current study is aimed to clarify whether repeated oxytocin alter plasma cytokine levels in relation to clinical changes of autism social core feature. Here we analyzed cytokine concentrations using comprehensive proteomics of plasmas of 207 adult males with high-functioning ASD collected from two independent multi-center large-scale randomized controlled trials (RCTs): Testing effects of 4-week intranasal administrations of TTA-121 (A novel oxytocin spray with enhanced bioavailability: 3U, 6U, 10U, or 20U/day) and placebo in the crossover discovery RCT; 48U/day Syntocinon or placebo in the parallel-group verification RCT...
March 8, 2024: Brain, Behavior, and Immunity